Sanofi's amlitelimab showed 35.9% (COAST-1) and 41.8% (COAST-2) of patients achieving 75% EASI reduction at 24 weeks in atopic dermatitis studies.1
Incyte's povorcitinib maintained responses in hidradenitis suppurativa through 54 weeks, with up to 71.4% achieving ≥50% reduction in abscess and inflammatory nodule counts.1
Roivant's brepocitinib demonstrated rapid itch reduction and 26.6% greater functional skin remission in dermatomyositis patients refractory to standard treatments.1
Alumis' envudeucitinib achieved PASI-90 in 53.1%-59.9% of psoriasis patients at 16 weeks and PASI-100 in 39.5%-41% at 24 weeks.1
Presentations occurred at the 2026 American Academy of Dermatology annual meeting in Orlando, Florida.1
Sources:
1. https://www.biospace.com/drug-development/aad-2026-sanofi-incyte-roivant-and-alumis-make-headway-into-skin-diseases